Filing Analysis
Alpha Cognition Inc. held its 2026 annual meeting of stockholders on June 16, 2026, resulting in the election of six directors and the ratification of CBIZ CPAs P.C. as auditors. The filing also notes a leadership change in the Board Chair position following the departure of Len Mertz.
🚩 Red Flags
- Departure of a director (Len Mertz) via non-re-election, though this is standard in annual meetings.
📋 Key Facts
- Annual meeting held on June 16, 2026; quorum was present with 10,535,277 shares represented.
- Dr. Robert Wills appointed as non-executive Chair of the Board.
- Len Mertz did not stand for re-election and has departed from the Board.
- Stockholders approved increasing the number of directors to six (6).
- All six nominees—Michael McFadden, Kenneth Cawkell, Rajeev ‘Rob’ Bakshi, Phillip Mertz, Robert Wills, and Bethany Sensenig—were elected.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the ensuing year.
Alpha Cognition Inc. filed an amendment to a previous 8-K to clarify the committee assignments for newly appointed director Bethany Sensenig. Ms. Sensenig has been appointed to the Audit and Governance and Nomination Committees, and will become Chair of the Audit Committee following the June 16, 2026 annual meeting.
📋 Key Facts
- Bethany Sensenig was appointed as a director on April 15, 2026.
- On April 28, 2026, the Board appointed Ms. Sensenig to the Audit Committee and the Governance and Nomination Committee.
- Ms. Sensenig is slated to become the Chair of the Audit Committee effective after the annual meeting of shareholders on June 16, 2026.
Alpha Cognition Inc. appointed Bethany Sensenig to its Board of Directors on April 15, 2026. Ms. Sensenig brings extensive biopharmaceutical experience, having previously served as CFO of Radius Health and in various leadership roles at Biogen.
📋 Key Facts
- Bethany Sensenig was appointed as a director effective April 15, 2026.
- Ms. Sensenig received an initial grant of 5,489 restricted stock units and 6,991 stock options with an exercise price of $6.65.
- Her professional background includes serving as CFO and Head of Operations at Radius Health (2024-2026) and 13 years at Biogen Inc.
- She currently serves on the boards of Supernus Pharmaceuticals (NASDAQ: SUPN) and KalVista Pharmaceuticals (NASDAQ: KALV).
Alpha Cognition Inc. entered into a settlement agreement with Galantos Pharma to buyout all future royalty and milestone obligations related to the Memogain asset for a one-time payment of EUR 5,214,220.
🚩 Red Flags
- Significant cash outlay of approximately EUR 5.2 million may impact short-term liquidity for a micro-cap entity.
📋 Key Facts
- Agreement signed on April 10, 2026, with Galantos Pharma GmbH i.L., a company in liquidation.
- One-time payment of EUR 5,214,220 to extinguish all remaining contingent royalty and milestone-related payments.
- The settlement amount represents an approximate 40% discount to the estimated market value of future obligations.
- The agreement relates to the original Memogain Asset Purchase Agreement dated August 23, 2013.
Alpha Cognition Inc. has scheduled its 2026 Annual General Meeting of Shareholders for June 16, 2026. The company established April 24, 2026, as the record date for shareholders entitled to vote at the meeting.
📋 Key Facts
- Annual General Meeting (AGM) date set for June 16, 2026.
- Record date for shareholder voting set for April 24, 2026.
- Notice of Meeting and Record Date filed with Canadian Securities Regulatory Authorities on March 27, 2026.
- The company is a British Columbia corporation listed on the Nasdaq Stock Market (ACOG).
Alpha Cognition Inc. announced its financial and operational results for the fiscal year ended December 31, 2025. The company also scheduled a management call to discuss these results.
📋 Key Facts
- Financial results reported for the fiscal year ended December 31, 2025.
- Press release issued on March 26, 2026.
- Management call announced to discuss operational and financial performance.
- The filing was made under Item 2.02 (Results of Operation and Financial Condition).
Alpha Cognition Inc. announced that Director Len Mertz will not stand for re-election at the 2026 annual meeting. Mr. Mertz will continue to serve on the Board until his current term expires at the meeting.
📋 Key Facts
- Director Len Mertz notified the Board of his decision on February 18, 2026.
- The departure is effective as of the Company’s 2026 Annual Meeting.
- The Company stated there were no disagreements regarding operations, policies, or practices.
- Mr. Mertz will remain in his role until the expiration of his current term.
Alpha Cognition Inc. announced equity awards granted to its CEO, COO, and Interim CFO on January 9, 2026, under the company's 2025 Stock and Incentive Plan.
🚩 Red Flags
- Retention of 'Interim' CFO suggests potential instability or ongoing search for permanent financial leadership.
📋 Key Facts
- CEO Michael McFadden granted 190,549 RSUs (3-year vest), 177,576 stock options, and 76,220 performance share units with price targets ranging from $12.00 to $28.00.
- COO Lauren D’Angelo granted 137,195 RSUs (3-year vest) and 106,545 stock options.
- Interim CFO Henry Du granted 20,579 RSUs (3-year vest) and 15,982 stock options.
- The awards were granted under the Company’s 2025 Stock and Incentive Plan.
Alpha Cognition Inc. has replaced its independent auditor, Manning Elliott LLP, with CBIZ CPAs P.C. The change is due to the company's relocation from Canada to Texas, as the previous auditor lacks a license in the new jurisdiction.
🚩 Red Flags
- None identified; the change is explicitly linked to jurisdictional licensing rather than audit disagreements.
📋 Key Facts
- Manning Elliott LLP resigned as the independent registered public accounting firm on October 10, 2025.
- The resignation is attributed solely to administrative licensing requirements following the company's relocation from Canada to Texas.
- CBIZ CPAs P.C. has been engaged as the new independent auditor.
- Manning Elliott stated there were no disagreements regarding accounting principles, practices, or financial disclosures.
- The previous auditor confirmed that reports for fiscal years 2023 and 2024 contained no adverse opinions, disclaimers, or qualifications.
Alpha Cognition Inc. has replaced its independent auditor from Manning Elliott LLP with CBIZ CPAs P.C. The change is driven by the company's relocation of its principal executive offices from Canada to Texas, as Manning Elliott lacks the necessary licensing in the state of Texas.
🚩 Red Flags
- Auditor change (though the reason provided is administrative/geographic rather than due to disagreements).
📋 Key Facts
- Manning Elliott LLP resigned as independent auditor on October 10, 2025.
- The resignation is due to administrative licensing requirements following the company's relocation from Canada to Grapevine, Texas.
- CBIZ CPAs P.C. has been engaged as the new independent registered public accounting firm.
- Manning Elliott stated there were no disagreements regarding accounting principles, practices, or auditing scope during their tenure.
- The company reports no 'reportable events' through September 11, 2025.
Alpha Cognition Inc. entered into an underwriting agreement on September 30, 2025, to conduct a public offering of common shares and pre-funded warrants. The company expects to raise approximately $35 million in gross proceeds to fund the commercial launch and marketing for its Alzheimer’s treatment products.
🚩 Red Flags
- Significant dilution expected due to the issuance of over 4.6 million new common shares and nearly 1 million pre-funded warrants.
- Pre-funded warrants with a near-zero exercise price ($0.001) act as immediate equity, contributing to rapid share count expansion.
📋 Key Facts
- Total expected gross proceeds: approximately $35.0 million (before expenses).
- Common shares offered: 4,651,516 at $6.25 per share.
- Pre-funded warrants offered: up to 948,484 at $6.249 per warrant (exercise price of $0.001).
- Underwriter: Titan Partners Group LLC (a division of American Capital Partners, LLC).
- Expected closing date: on or about October 2, 2025.
- Lock-up period: Directors and executive officers are subject to a 75-day lock-up following the closing.
- Use of proceeds: Commercial launch acceleration, sales expansion, marketing investment, and reimbursement infrastructure for Alzheimer's treatment.
Alpha Cognition Inc. entered into an At-the-Market (ATM) offering agreement with H.C. Wainwright & Co., LLC to sell up to $75 million in common shares at market prices.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $75M offering cap.
- ATM offerings are often used by micro-cap companies to raise immediate working capital, which can create downward pressure on the stock price during sales periods.
📋 Key Facts
- Entered into ATM Agreement on August 22, 2025.
- Sales agent: H.C. Wainwright & Co., LLC.
- Aggregate gross sales value cap: US$75.0 million.
- Commission rate to agent: up to 3.0% of gross sales price.
- Shares will be sold on the Nasdaq Capital Market at market prices via Rule 415 transactions.
Alpha Cognition Inc. held its 2025 annual meeting of stockholders on June 19, 2025. The results included the approval of a new 2025 Stock Incentive Plan, the election of six directors, and the ratification of Manning Elliot LLP as the independent auditor.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual meeting held on June 19, 2025, with a quorum present (8,404,660 shares represented).
- Stockholders approved the adoption of the 2025 Stock Incentive Plan to provide equity-based compensation.
- Six nominees were elected to the Board: Michael McFadden, Kenneth Cawkell, Rajeev ‘Rob’ Bakshi, Len Mertz, Phillip Mertz, and Robert Wills.
- Manning Elliot LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- The number of directors was set at six via Proposal No. 1.
Alpha Cognition Inc. announced the departure of director John Havens and the appointment of Dr. Robert Wills to the Board and Governance and Nominating Committee.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- John Havens will not run for re-election at the 2025 annual meeting; no disagreement with company reported.
- Dr. Robert Wills appointed to the Board and Governance and Nominating Committee effective April 7, 2025.
- Dr. Wills has extensive biotech experience, including roles at Johnson & Johnson and Chairman of Milestone Pharmaceuticals (Nasdaq: MIST).
- Dr. Wills to receive $40,000 annual base salary and $5,000 for committee service.
- Dr. Wills granted 35,575 stock options with an exercise price of $4.83 per share, vesting over 24 months.
Alpha Cognition Inc. announced new executive and director compensation packages for fiscal year 2025 following a benchmarking review by an independent consultant.
🚩 Red Flags
- Significant increase in executive equity compensation ($2.5M for CEO) which may lead to future dilution.
📋 Key Facts
- CEO Michael McFadden's total target compensation is $3,500,000 ($625k base, $375k bonus, $2.5M stock options).
- COO Lauren D’Angelo's total target compensation is $2,300,000 ($500k base, $300k bonus, $1.5M stock options).
- Compensation was benchmarked against a peer group of 14 companies to align with the 50th percentile.
- Board Chair Len Mertz will receive his salary in the form of stock options instead of cash.
- Non-employee directors received a $100,000 'catch-up' one-time equity award due to foregone compensation.
Alpha Cognition Inc. issued a representative's purchase warrant to Titan Partners Group LLC as part of an underwriting agreement. The warrant allows for the purchase of up to 34,196 shares at an initial exercise price of $7.18 per share.
🚩 Red Flags
- Issuance of warrants to underwriters is a standard component of financing but can lead to future dilution.
📋 Key Facts
- Date of event: December 16, 2024
- Issuer of warrant: Alpha Cognition Inc.
- Recipient: Titan Partners Group LLC (Representative for Underwriters)
- Total shares under warrant: Up to 34,196 shares of Common Stock
- Initial exercise price: $7.18 per share
- Exercise period: June 14, 2025, through November 8, 2029
Alpha Cognition Inc. completed a significant public offering of 8,695,653 common shares/pre-funded warrants on November 13, 2024, raising approximately $46.15 million in net proceeds. The offering included the issuance of underwriter warrants and the conversion of existing senior convertible notes.
🚩 Red Flags
- Significant dilution: The issuance of over 8.6 million shares at a nominal exercise price ($0.0001) represents massive equity dilution for existing shareholders.
- Warrant overhang: Issuance of substantial underwriter warrants and additional warrants to note holders creates potential future selling pressure.
📋 Key Facts
- Completed an offering of 8,695,653 common shares/pre-funded warrants on November 13, 2024.
- Net proceeds from the offering are approximately $46.15 million (potentially up to $52.48 million if underwriters exercise their option).
- The exercise price for the pre-funded warrants is $0.0001 per share.
- Issued 608,696 Underwriter Warrants at an exercise price of $7.18 per share (later adjusted to $7.19) exercisable from May 8, 2025, to November 13, 2029.
- Converted senior convertible notes into 801,412 common shares at a conversion price of $5.75 per share.
- Issued 215,418 additional warrants to previous note holders as part of the offering terms.
Alpha Cognition Inc. has implemented a 1-for-25 reverse stock split effective November 5, 2024. The consolidation was executed to address Nasdaq minimum share price compliance requirements.
🚩 Red Flags
- Reverse stock split is a common indicator of significant downward pressure on share price and potential delisting risk.
- The filing explicitly states the move was intended to meet Nasdaq minimum share price requirements, confirming the company's struggle with market valuation/compliance.
📋 Key Facts
- Reverse split ratio: 1-for-25 (one new share for every 25 old shares).
- Effective Date: Open of markets on November 5, 2024.
- Purpose: To meet Nasdaq Capital Market minimum share price requirements.
- Authorized shares reduced from approximately 150,855,536 to roughly 6,034,221.
- No change to stock symbol or par value (no par value remains).
- New CUSIP: 02074J501; New ISIN: CA02074J5017.
Alpha Cognition Inc. announced a change in its financial leadership effective October 21, 2024. Interim Principal Accounting and Financial Officer Jay Yoo resigned, and Henry Du was appointed as Vice President of Finance and Accounting and interim CFO.
🚩 Red Flags
- Sudden departure of the interim Principal Accounting and Financial Officer (Jay Yoo) on the same day as the new appointment.
- The company is currently using an 'interim' CFO, suggesting a lack of permanent financial leadership in a micro-cap environment.
📋 Key Facts
- Jay Yoo resigned as interim Principal Accounting and Financial Officer on October 21, 2024.
- Henry Du appointed as VP of Finance and Accounting and interim CFO effective October 21, 2024.
- Mr. Du has over 20 years of experience in corporate accounting/finance, including roles at Amplify Surgical and HUYABIO International.
- Mr. Du's compensation includes a $275,000 base salary and a 40% annual bonus target.
- Mr. Du received an initial grant of 800,000 stock options vesting quarterly over 12 quarters.
Alpha Cognition Inc. has appointed Jay Yoo as interim Principal Accounting and Financial Officer effective October 2, 2024. This follows the departure of former CFO Don Kalkofen, whose transition period was truncated after a mutual agreement to end his part-time services early.
🚩 Red Flags
- Sudden termination of a CFO's transition/consulting period following their resignation.
- Use of interim accounting leadership via an external consultancy firm, often seen in companies undergoing rapid financial restructuring or facing reporting challenges.
📋 Key Facts
- Jay Yoo appointed as interim Principal Accounting and Financial Officer effective Oct 2, 2024.
- Mr. Yoo is being provided via CFO Vertical, LLC, an interim resource firm.
- Former CFO Don Kalkofen resigned effective Oct 1, 2024.
- The previously planned transition period for Mr. Kalkofen (Oct 1 to Nov 30) has been terminated by mutual agreement.
Alpha Cognition Inc. held its annual meeting of shareholders on September 27, 2024, where all proposals were passed, including the election of six directors and the ratification of Manning Elliott LLP as auditor. Notably, shareholders approved an amendment to increase the quorum requirement from 5% to 33 1/3% of outstanding shares.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on September 27, 2024.
- Quorum for the meeting was 150,855,536 shares (47.62% of issued and outstanding common shares).
- Shareholders approved an amendment to increase quorum requirements from 5% to 33 1/3%.
- Six directors were elected: Michael McFadden, Kenneth Cawkell, Rajeev Rob Bakshi, Len Mertz, John Havens, and Phillip Mertz.
- Manning Elliott LLP was re-appointed as the independent registered public accounting firm.
This is an amendment (8-K/A) to a previous filing intended solely to correct typographical errors in a Securities Purchase Agreement dated September 24, 2024. The underlying event involves the execution of a new securities purchase agreement.
🚩 Red Flags
- The amendment refers to a Securities Purchase Agreement (Exhibit 10.1), which typically indicates potential dilution for existing shareholders.
📋 Key Facts
- Filing date: September 26, 2024 (Amendment No. 1).
- The filing is an amendment to correct typographical errors in Exhibit 10.1 of the original 8-K filed on September 25, 2024.
- The primary event being corrected relates to a Securities Purchase Agreement dated September 24, 2024.
- Company is classified as an 'emerging growth company'.
Alpha Cognition Inc. entered into a Securities Purchase Agreement to issue senior convertible notes and warrants for approximately $4.545 million in gross proceeds. The funds are intended for general corporate purposes and to meet specific debt obligations under a promissory note with Neurodyn Life Sciences Inc.
🚩 Red Flags
- High interest rate (10%) that doubles to 20% upon default.
- Strict covenants including a prohibition on reverse stock splits without holder consent.
- Significant 'Events of Default' triggers, including failure to file SEC reports or maintain listing.
- Bankruptcy Event of Default includes a 125% redemption premium payable in cash.
- The company is using proceeds specifically to meet existing debt obligations (Neurodyn Life Sciences Inc.).
- Potential for significant dilution via the conversion price and warrants.
📋 Key Facts
- Aggregate gross proceeds: approximately $4.545 million.
- Instrument type: Senior Convertible Notes and Warrants.
- Maturity Date: September 24, 2026.
- Interest Rate: 10.00% per annum (increases to 20.00% upon Event of Default).
- Conversion Price: $0.422 per share.
- Mandatory Conversion Trigger: A 'Qualified Offering' defined as an offering of at least $10 million in aggregate gross proceeds coinciding with a US national securities exchange uplisting.
- Automatic Conversion Trigger: If common shares close at ≥250% of the conversion price for 10 consecutive trading days and are registered for resale.
Alpha Cognition Inc. filed an 8-K to announce the filing of management information circulars and proxy materials with Canadian securities commissions. This is a routine administrative filing related to the company's upcoming Annual General Meeting (AGM).
📋 Key Facts
- The Company filed a management information circular dated August 21, 2024.
- An Annual Meeting of shareholders is scheduled for September 27, 2024.
- The record date for shareholder voting eligibility was August 21, 2024.
- Meeting materials were filed via SEDAR+ in Canada.
Alpha Cognition Inc. announced the resignation of its Chief Financial Officer, Don Kalkofen, effective October 1, 2024. To mitigate transition risks, Mr. Kalkofen will serve as a consultant from October 2024 through November 2025.
🚩 Red Flags
- Departure of a key C-suite executive (CFO) can create operational instability in micro-cap companies.
- The need for a 14-month consulting arrangement suggests a prolonged period of leadership uncertainty or difficulty in finding a permanent replacement.
📋 Key Facts
- Don Kalkofen resigned as CFO on August 21, 2024.
- Resignation becomes effective October 1, 2024.
- Kalkofen will transition to a part-time consultant role from October 1, 2024, through November 30, 2025.
- The consultancy is intended to assist with accounting matters and the transition to an interim CFO.
Alpha Cognition Inc. filed an 8-K to furnish its quarterly financial and operational results for the period ending June 30, 2024. The filing serves as a formal announcement of the company's recent performance via a press release.
📋 Key Facts
- Reporting date: August 12, 2024
- Period covered: Quarter ended June 30, 2024
- The filing is for 'furnishing' purposes under Regulation FD rather than formal 'filing' for liability purposes.
- Company is classified as an emerging growth company.
Alpha Cognition Inc. has approved a new corporate quorum policy to support its proposed Nasdaq listing. The requirement for shareholder meetings increases from 5% to 33 1/3% of issued and outstanding common shares.
🚩 Red Flags
- Significant increase in quorum requirement (from 5% to 33.33%) can make it more difficult for the company to conduct official business or pass resolutions if shareholders do not participate.
📋 Key Facts
- Board approval date: August 6, 2024
- Quorum requirement increased from 5% to 33.33% (one-third) of issued and outstanding common shares
- The change is intended to support the Company's proposed listing on the Nasdaq Capital Market
- Policy takes immediate effect as a corporate shareholder meeting policy
Alpha Cognition Inc. announced that the FDA has granted approval for its drug ZUNVEYL® (benzgalantamine) to treat mild-to-moderate Alzheimer's disease. This represents a major regulatory milestone for the company's lead product candidate.
📋 Key Facts
- FDA approved ZUNVEYL® (benzgalantamine), formerly known as ALPHA-1062.
- Indication: Treatment of mild-to-moderate Alzheimer's disease.
- Announcement date: July 29, 2024.
Alpha Cognition Inc. entered into an Agreement and Waiver with Spartan Capital Securities, LLC to facilitate a planned offering with Alliance Global Partners/A.G.P. The agreement involves a reduction in transaction fees and the waiver of future rights by Spartan Capital.
🚩 Red Flags
- None identified in this specific filing; fee reduction and waiver typically suggest a restructuring of advisory terms to facilitate new capital raising.
📋 Key Facts
- Date of event: June 10, 2024
- Spartan Capital Securities, LLC agreed to reduce its fee from 2.5% to 1% specifically for the planned offering with Alliance Global Partners/A.G.P.
- Spartan Capital waived all future rights under their existing Investment Banking Agreement upon the closing of the Transaction.
- The company is classified as an emerging growth company.